The Aroon Indicator for ARTL entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 257 similar instances where the Aroon Indicator formed such a pattern. In 243 of the 257 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARTL as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARTL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence (MACD) for ARTL just turned positive on September 30, 2026. Looking at past instances where ARTL's MACD turned positive, the stock continued to rise in 43 of 53 cases over the following month. The odds of a continued upward trend are 81%.
Following a +78.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARTL advanced for three days, in 167 of 218 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.280) is normal, around the industry mean (2.973). P/E Ratio (-0.025) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. ARTL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CRMD moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 29 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on CRMD as a result. In 64 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for CRMD just turned positive on October 15, 2026. Looking at past instances where CRMD's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
The 50-day moving average for CRMD moved above the 200-day moving average on October 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +7.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRMD advanced for three days, in 228 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for CRMD crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
CRMD broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CRMD entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. CRMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 77 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.370) is normal, around the industry mean (2.973). P/E Ratio (3.293) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (5.636) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.564) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ARTL | CRMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 98 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | 87 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 77 | |
SMR RATING 1..100 | 100 | 19 | |
PRICE GROWTH RATING 1..100 | 96 | 59 | |
P/E GROWTH RATING 1..100 | 97 | 96 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARTL's Valuation (53) in the null industry is somewhat better than the same rating for CRMD (87) in the Medical Specialties industry. This means that ARTL’s stock grew somewhat faster than CRMD’s over the last 12 months.
CRMD's Profit vs Risk Rating (77) in the Medical Specialties industry is in the same range as ARTL (100) in the null industry. This means that CRMD’s stock grew similarly to ARTL’s over the last 12 months.
CRMD's SMR Rating (19) in the Medical Specialties industry is significantly better than the same rating for ARTL (100) in the null industry. This means that CRMD’s stock grew significantly faster than ARTL’s over the last 12 months.
CRMD's Price Growth Rating (59) in the Medical Specialties industry is somewhat better than the same rating for ARTL (96) in the null industry. This means that CRMD’s stock grew somewhat faster than ARTL’s over the last 12 months.
CRMD's P/E Growth Rating (96) in the Medical Specialties industry is in the same range as ARTL (97) in the null industry. This means that CRMD’s stock grew similarly to ARTL’s over the last 12 months.
| ARTL | CRMD | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 90% |
| Stochastic ODDS (%) | N/A | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 89% | 1 day ago 73% |
| MACD ODDS (%) | 1 day ago 81% | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 79% |
| TrendMonth ODDS (%) | 1 day ago 88% | 1 day ago 80% |
| Advances ODDS (%) | about 1 month ago 77% | 1 day ago 81% |
| Declines ODDS (%) | 1 day ago 89% | 21 days ago 85% |
| BollingerBands ODDS (%) | N/A | 1 day ago 79% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARTL’s FA Score shows that 0 FA rating(s) are green while CRMD’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARTL’s TA Score shows that 2 TA indicator(s) are bullish while CRMD’s TA Score has 5 bullish TA indicator(s).
ARTL (@Biotechnology) experienced а -11.11% price change this week, while CRMD (@Biotechnology) price change was +8.58% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
ARTL is expected to report earnings on Nov 11, 2026.
CRMD is expected to report earnings on Nov 11, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ARTL has been loosely correlated with PALI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ARTL jumps, then PALI could also see price increases.
| Ticker / NAME | Correlation To ARTL | 1D Price Change % | ||
|---|---|---|---|---|
| ARTL | 100% | -0.39% | ||
| PALI - ARTL | 34% Loosely correlated | -3.57% | ||
| CRMD - ARTL | 32% Poorly correlated | +3.98% | ||
| FATE - ARTL | 31% Poorly correlated | +0.97% | ||
| LSTA - ARTL | 29% Poorly correlated | -4.29% | ||
| SPRO - ARTL | 28% Poorly correlated | -3.42% | ||
More | ||||